We also found that companies that currently offer GLP-1s will continue doing so at an astounding rate of 99%.[1] This is primarily driven by employee interest and engagement despite the perceived higher costs associated with these treatments
"I am a very good use case of how you can do everything eat healthy, work out to the point of even playing a professional sport and getting to the finals of Wimbledon and U.S
It's effective for both men and women
Kaddour-Djebbar I, Choudhary V, Brooks C, Ghazaly T, Lakshmikanthan V, Dong Z, et al
Clinical Trials Using Senolytics The enthusiasm for senescent cell clearance across diseases of aging, along with a therapeutic approach that could be translated to patients, led to the first clinical trial of senolytic therapy (D+Q) in adults with idiopathic pulmonary fibrosis (IPF)